Riccardo Panella got his master degree in Biotechnology as well as his Ph.D. in Molecular Oncology in at the University of Perugia in Italy after which he was awarded a post-doctoral fellowship from the Marie Curie Foundation in 2014. He worked for six years as a Post-Doctoral fellow at Beth Israel Deaconess Medical Center Cancer Institute / Harvard Medical School Cancer Center.
Riccardo Panella has focused his entire career on translational medicine, with the main goal of developing new treatment options and new therapeutic approaches to disease. His expertise lies in the application of non-coding RNA as both a therapeutic target and as cutting-edge technology for developing new therapeutic paradigms.
He is now serving as Associate Professor at the Center for RNA medicine in the Copenhagen campus of Aalborg University in Denmark and he is leading a team that is currently investigating the role of non-coding RNAs in metabolic homeostasis and how it affects human metabolism. In parallel to his academic activity, he also found a company called Resalis Therapeutic with the main goal of developing an innovative RNA based approach for the cure of obesity and non alcoholic liver disease.